In new Regeneron deal for COVID drug, White House imposes price limits for first time

By STAT News
| September 14, 2023

A groundbreaking clause in a new deal between HHS and Regeneron marks the first time the Biden administration has directly used its leverage to challenge drugmakers' list prices.

Full story

#1

Recent research on Paxlovid shows there is "solid data on its effectiveness," a co-author of the study told HealthLeaders. ...

One of the most important elements of a company’s success is also one of the least tangible —culture. ...